QWM
NTLA icon

Quadcap Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Quadcap Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,799
Closed -$169K – 413
2025
Q3 		$169K Buy
+9,799
New +$121K 0.02% 385
2024
Q2 		– Sell
-7,916
Closed -$218K – 401
2024
Q1 		$218K Sell
7,916
-2,542
-24% -$70.6K 0.05% 303
2023
Q4 		$319K Buy
+10,458
New +$301K 0.08% 263

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadcap Wealth Management's NTLA Position: Q4 2025 in Review

Quadcap Wealth Management sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 9,799 shares — an estimated $169K sold.

Quadcap Wealth Management first reported a position in NTLA in Q4 2023 and held it in 3 quarters. The position peaked at $319K in Q4 2023. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Quadcap Wealth Management reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadcap Wealth Management sold 9,799 Intellia Therapeutics shares in Q4 2025, an estimated $169K.
  • Quadcap Wealth Management first reported a position in Intellia Therapeutics in Q4 2023 and held it in 3 quarters.
  • Quadcap Wealth Management's Intellia Therapeutics position peaked at $319K in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Quadcap Wealth Management's 13F filing for Q4 2025, filed 29 Jan 2026.